TMCnet News
Thrasos to Present at the 22nd Annual BioCentury NewsMakers and 8th Annual BioPharm America ConferencesThrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced today that it will be participating in two key meetings in September, BioCentury NewsMakers and BioPharm America. Richard Andrews President and Chief Executive Officer will present a company overview at the 22nd Annual BioCentury NewsMakers in the Biotech Industry Conference on Thursday, September 10th. The BioCentury NewsMakers Conference takes place at the Millennium Broadway Hotel and Conference Center in New York City. Mr. Andrews will present at 10:00 a.m. in Room 402/403. A Breakout Session will immediately follow the presentation in Room 401. In addition, Mr. Andrews will also be participating in a panel discussion at the 8th Annual BioPharm America International Partnering Conference on Tuesday, September 15. The BioPharm America Conference takes place at the Bosto Marriott Copley Place. Mr. Andrews will be participating in a panel discussion entitled "How does pharma get involved in an outside-the-box idea" from 4:00-5:00 p.m. in Provincetown, Level 4. During this panel industry executives will discuss why pharmaceutical companies typically go after the same five therapeutic areas, and explore the potential for success in some of the overlooked diseases. About Thrasos Thrasos is a privately held, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184, is currently being evaluated in a Phase 2 clinical study for the prevention of Acute Kidney Injury (AKI) in patients undergoing cardiac surgery. The company believes that its technology will be broadly applicable to other types of major surgery where AKI is also a significant complication. In addition, Thrasos is developing compounds for Chronic Kidney Disease, which can result in permanent loss of kidney function and the need for dialysis. The Company is headquartered in Montreal, Canada, with a satellite office in Boston, Massachusetts. www.thrasos.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005426/en/ |
